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Abstract 
 
Dementia with Lewy bodies (‘Lewy body dementia' or ‘diffuse Lewy body disease') 
(DLB) is the second commonest form of dementia to affect elderly people after 
Alzheimer’s disease. A combination of the clinical symptoms of Alzheimer’s disease 
and Parkinson's disease is present in DLB and the disorder is classified as a 
‘parkinsonian syndrome’, a group of diseases which also includes Parkinson’s 
disease, progressive supranuclear palsy, corticobasal degeneration, and multiple 
system atrophy. Characteristic of DLB are: (1) fluctuating cognitive ability with 
pronounced variations in attention and alertness, (2) recurrent visual hallucinations, 
and (3) spontaneous motor features including akinesia, rigidity, and tremor. In 
addition, DLB patients may exhibit visual signs and symptoms including defects in 
eye movement, pupillary function, and in complex visual functions. Visual symptoms 
may aid the differential diagnosis of the parkinsonian syndromes. Hence, the presence 
of visual hallucinations supports a diagnosis of Parkinson’s disease or DLB rather 
than progressive supranuclear palsy. DLB and Parkinson’s disease may exhibit 
similar impairments on a variety of saccadic and visual perception tasks (visual 
discrimination, space-motion, and object-form recognition). Nevertheless, deficits in 
orientation, trail-making, and in reading the names of colours are often significantly 
greater in DLB than in Parkinson’s disease. As primary eye-care practitioners, 
optometrists should be able to identify work with patients with DLB and their carers 
to manage their visual welfare. 
 
Key words: Dementia with Lewy bodies (DLB), Progressive supranuclear palsy, 
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Introduction 
 
Previous reviews have described the visual signs and symptoms of two ‘parkinsonian 
syndromes’, viz., Parkinson’s disease (Parkinson’s disease)1 and progressive 
supranuclear palsy (progressive supranuclear palsy).2 Patients with Parkinson’s 
disease and progressive supranuclear palsy may exhibit defects in primary vision, eye 
movement, pupillary function, and in complex visual functions involving the ability 
to judge distances or to make out the shape of an object.1,2 Differential diagnosis of 
the parkinsonian syndromes, however, can be difficult owing to overlapping clinical 
features and visual signs and symptoms may help to distinguish the various disorders. 
Particularly useful in separating progressive supranuclear palsy from Parkinson’s 
disease, for example, is the presence in the former of vertical supranuclear gaze palsy, 
fixation instability, lid retraction, blepharospasm, and apraxia of eyelid opening and 
closing.1,2 
 
Dementia with Lewy bodies (DLB) (also known as 'Lewy body dementia' or ‘diffuse 
Lewy body disease') is the second most common form of dementia after Alzheimer’s 
disease (Alzheimer’s disease)3,4 and may account for up to a quarter of all cases of 
dementia in elderly people. It is characterised by a progressive disabling mental 
impairment and includes fluctuating cognition, visual hallucinations, and 
parkinsonism as typical features. Hence, DLB is also classified as a parkinsonian 
syndrome and may be associated with a variety of visual problems which, although 
they may overlap with those of progressive supranuclear palsy and Parkinson’s 
disease, can aid clinical diagnosis. Therefore, the main objectives of this review are: 
(1) to describe the general features of DLB, (2) to evaluate the visual signs and 
symptoms reported in the disorder, (3) to discuss those visual features which may 
help in the differential diagnosis of DLB, and (4) to consider the role of the 
optometrist in managing DLB.  
 
General features 
 
Incidence and prevalence 
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There have been relatively few studies of the incidence and prevalence of DLB. 
Between 1999 and 2001, the incidence of a diagnosis of DLB among patients 
attending the Santa Caterina Hospital in Girona, Spain was 26/100,000 cases per 
year.5 In addition, incidence increased with age and there was a preponderance of 
males (63%) in the sample. This study, however, does not provide an unbiased 
estimate of the incidence of DLB as patients were referred from primary health 
centres. A review of all studies reporting the prevalence of DLB6, suggested estimates 
in the range 0 – 5% of the general population and up to 30.5% of all dementia cases. 
Incidence was estimated to be 0.1% a year for the general population and 3.2% for all 
new dementias. The most recent estimates of incidence of DLB relate to an elderly 
French population assessed over 15 years.7 Incidence was estimated to be 
112/100,000 person-years and increased continuously with age even in the oldest 
individuals. 
 
Signs and symptoms 
 
The original ‘concept’ of DLB was based on the clinical description of patients 
exhibiting ‘paralysis agitans’ associated with a typical brain pathology, viz., the 
intracellular ‘inclusions’ known as Lewy bodies (LB).8 The most important general 
feature of DLB is a progressive decline in the mental ability of the patient of 
sufficient magnitude to interfere with normal social or occupational function (Table 
1).4 Prominent and persistent memory impairments may not necessarily occur in the 
early stages of DLB, but are usually evident at some stage of the disease. Problems of 
attention and in visuo-spatial ability are common, the latter including difficulties in 
drawing the shapes of common objects such as a clock or in copying figures. The 
majority of patients with DLB exhibit at least two of the following 'core' features:4 (1) 
fluctuating cognitive ability with pronounced variations in attention and alertness, (2) 
recurrent visual hallucinations that are typically well-formed and detailed, and (3) the 
spontaneous motor features characteristic of parkinsonian syndromes in general.10,11 
Hence, typical Parkinson’s disease features which may be present in DLB include 
shuffling gait, reduced arm-swinging while walking, blank expression, rigidity, 
‘ratchet-like’ cogwheeling movements, low speech volume, and difficulties in 
swallowing.  There may be two distinct clinical syndromes: (1) DLB in which there is 
a combination of dementia and parkinsonism characterised by prominent 
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hallucinations, and rapid eye movement (REM) sleep behavioural disorder, and 2) 
DLB with ‘parkinsonian dementia syndrome’ in which the symptoms of parkinsonism 
predominate.12 
 
Dementia is defined as a deterioration of intellectual capacity often affecting 
memory, concentration, cognitive ability, and judgement.  In DLB, dementia either 
precedes the symptoms of parkinsonism or the two symptoms appear together. About 
a third of Parkinson’s disease patients also develop a progressive dementia and may 
exhibit the characteristic neuropathology of DLB after death further blurring the 
distinction between the two disorders.11 In DLB, these symptoms are associated with 
impaired psychomotor speed, visuo-spatial, and executive functions, i.e., an inability 
to carry out the normal and familiar tasks of life, but with the relative preservation of 
language. 
 
In addition, several features, although not in themselves diagnostic of DLB, would 
support such a diagnosis, viz., repeated falls, syncope (fainting due to a sudden fall in 
blood pressure), transient loss of consciousness, sensitivity to neuroleptic drugs, 
delusions, and other types of sensory hallucination.13 Rapid eye movement (REM) 
sleep behavioural disorder is often regarded as a sign of impending DLB.14 By 
contrast, features less suggestive of DLB include any evidence of vascular disease, 
such as stroke, or the presence of other types of brain disorder which could account 
for the clinical symptoms. Males may be more susceptible than females and often 
have a worse prognosis.15  
 
Functional imaging 
 
A number of functional imaging studies have been carried out on patients with DLB 
and the results compared with Alzheimer’s disease. Within the temporal lobe, for 
example, the volume of the hippocampus (HC) and parahippocampal gyrus (PHG) is 
usually greater in DLB than in Alzheimer’s disease and may be responsible for the 
relative preservation of memory function in DLB.16 In addition, relative cerebral 
blood flow is usually lower in the occipital cortex and higher in the medial temporal 
lobe in DLB compared with Alzheimer’s disease.17 Moreover, both DLB and 
Alzheimer’s disease show significant reductions in metabolism in the parietal and 
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temporal cortex, the posterior cingulate gyrus (CG), and frontal association areas,18 
but only in DLB is there a significant reduction in the occipital cortex and especially 
in the primary visual area (V1). Occipital hypometabolism may be a useful potential 
marker to distinguish DLB from Alzheimer’s disease. In common with Alzheimer’s 
disease and vascular dementia, periventricular and white matter hyperintensities are 
more extensive in DLB compared with elderly control patients.19  
 
Neuropathology 
 
Confirmation of the presence of DLB is often only possible after death and 
subsequent post-mortem. The degree of gross brain atrophy has been described as 
broadly similar in DLB and Alzheimer’s disease20 but in other studies, the size of 
parietal, frontal, and temporal lobes was reported to be intermediate between those of 
Alzheimer’s disease and elderly control brains.21 In addition, little evidence of 
atrophy of the occipital lobes has been observed despite the reported 
hypometabolism. The major brain areas affected by the pathology of DLB, based on 
neuropathological and functional imaging data, are shown in Fig 1. In the cerebral 
cortex, areas of the temporal lobe such as the superior temporal gyrus (STG) and 
PHG are affected together with limbic system areas including the HC and amygdala 
(A). Other cortical regions involved include the CG, the insula and claustrum (I/C), 
the superior frontal cortex (SFC), and the occipital cortex (OC). The basal ganglia are 
also affected, including the putamen and caudate nucleus, but the globus pallidus 
appears to be spared.22,23 The pigmented nuclei of the brain stem, such as the 
substantia nigra and the locus caeruleus, are also likely to exhibit pathological 
changes. 
 
The essential feature necessary for a neuropathological diagnosis of DLB is the 
presence of the characteristic LB (Fig 2).1 Lewy bodies have also been observed in 
Parkinson’s disease, but have a different distribution in the brain than in DLB. In 
DLB, there are significant numbers of LB in the cerebral cortex whereas in 
Parkinson’s disease, LB are largely confined to the substantia nigra in the midbrain.1 
The density of LB in various brain areas were studied in 12 cases of DLB and are 
shown in Fig 3.24 The greatest densities of LB were recorded in the temporal lobe and 
in limbic regions, especially the PHG, amygdala, and STG. Significant numbers of 
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LB are also observed in the substantia nigra, as in Parkinson’s disease, and in the 
insula while fewer LB have been recorded in the frontal, parietal, and occipital 
regions.25 
  
Lewy bodies themselves (Fig 2) are spherical structures found in the cytoplasm of 
affected cells and can be visualised in histological sections by a variety of staining 
and immunolabelling techniques including haemotoxylin and eosin, alpha-B-
crystallin, ubiquitin, and most significantly, -synuclein. -Synuclein is also found in 
LB in the brains of cases of Parkinson’s disease and in the rare parkinsonian 
syndrome multiple system atrophy (MSA) and thus, unites these disorders as a major 
molecular group of neurodegenerative disorders, the ‘synucleinopathies’.26 The 
synucleins themselves are small proteins (123-143 amino acids), localized to 
presynaptic terminals, and may be involved in neurotransmission and/or synaptic 
organisation.27  
 
Pathological changes may also occur in DLB which resemble those of Alzheimer’s 
disease9 including the presence of inclusions termed neurofibrillary tangles (NFT) 
and extracellular protein deposits known as senile plaques (SP).9 The density of these 
pathological changes is significant enough in some DLB cases to conclude that they 
have a combined or 'mixed' disease, i.e., DLB in association with Alzheimer’s 
disease.24  Hence, cases which combine the features of DLB and Alzheimer’s disease, 
as well as overlap with parkinsonian syndromes,28 can make the clinical and 
pathological diagnosis of DLB especially difficult.  
 
Aetiology 
 
There is no evidence that DLB is an infectious disease or that it can spread from one 
individual to another. The majority of cases occur sporadically but genetic factors, 
previously thought to be unimportant, may be involved to some extent. Hence, 
missense mutations in exons 3 and 4 of the -synuclein gene have been observed in 
rare cases of familial DLB29 but in other studies no such associations have been 
found.30  In addition, cases of DLB in three generations of a Belgian family have been 
linked to a region of chromosome 2 (2q35-q36) adjacent to the previously described 
PARK11 gene.31 As in Alzheimer’s disease, allelic variations in the apolipoprotein E 
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(Apo E) gene have been identified as a risk factor for DLB.32,33 Hence, individuals 
with DLB have an increased frequency of Apo E allele 4 compared with non-
demented elderly controls. The presence of the 4 allele may accelerate the 
development of Alzheimer’s disease-type pathology within the aged brain and hence, 
is often associated with an earlier onset of the disease.  
 
Treatment 
 
There is no effective cure for DLB and existing treatments usually confer small 
benefits to the patient and are essentially palliative. The observation that DLB, 
Alzheimer’s disease, and Parkinson’s disease share overlapping clinical and 
pathological features suggests that treatments used in Alzheimer’s disease and 
Parkinson’s disease could also be effective in DLB. For example, a more severe 
neurotransmitter deficit involving the cholinergic system is often seen in DLB 
compared with Alzheimer’s disease suggesting that cholinergic therapy may be more 
effective. The cholinergic deficit in DLB is often associated with less prominent 
cerebral atrophy and neuronal damage than is observed in Alzheimer’s disease and 
hence, encouraging results have been obtained when DLB patients have been treated 
with cholinesterase inhibitors such as rivastigmine, donepezil, and galatamine.34 
Nevertheless, parkinsonian motor signs in DLB, such as rigidity and bradykinesia, 
may be less amenable to conventional dopamine therapies than in Parkinson’s 
disease35, e.g., sinemet may help movement problems but in some cases may 
aggravate psychosis in DLB. In addition, DLB is more sensitive than Alzheimer’s 
disease to the adverse effects of antipsychotic agents, and especially the older 
‘typical’ antipsychotic drugs such as haloperidol, which can cause the extrapyramidal 
signs and symptoms typical of Parkinson’s disease, and may even lead to an early 
death.34 Hence, caution is needed in the treatment of visual hallucinations and other 
psychotic symptoms in DLB. In addition, medications used to treat urinary 
incontinence, and antihistamines such as benadry, may exacerbate the symptoms of 
dementia. Clonazepam may be useful in the treatment of REM sleep behavioural 
disorder. 
 
Visual signs and symptoms 
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A summary of the visual signs and symptoms that have been reported in DLB to date 
is given in Table 2. For the purpose of this article, they will be divided into those 
affecting: (1) visual acuity, (2) visual fields, (3) eye movement, (4) blink reflex and 
pupil reactivity, (5) electrophysiology, (6) complex visual functions, (7) visual 
hallucinations, and (8) REM sleep behaviour disorder. 
 
Visual acuity 
 
Visual acuity in DLB is essentially similar to that seen in control patients of similar 
age36 suggesting that the visual pathway from eye to brain is relatively preserved. 
Hence, it is the higher level visual areas involved in more complex visual functions 
which are more likely to be impaired in DLB.36  
 
Visual fields 
 
There have been relatively few studies to date on the visual field defects in any 
parkinsonian syndrome including DLB.1,2 A 66 year-old patient diagnosed with DLB, 
however, developed a left homonymous hemianopia early in the disease process.37 
Large numbers of NFT were observed in the right striate, peristriate, and inferior 
temporal cortex of this patient. In addition, studies of regional cerebral blood flow 
have suggested significant hypoperfusion in occipital areas in DLB and this could 
also lead to the development of significant visual field problems.38 As a consequence, 
studies of the incidence and type of visual field problem in DLB are urgently needed. 
 
Eye movement  
 
A variety of eye movement problems have been reported in patients with Parkinson’s 
disease1 and in progressive supranuclear palsy2 including abnormal saccadic and 
smooth pursuit eye movements, abnormal optokinetic nystagmus  ('train nystagmus'), 
and convergence.39 DLB patients specifically have been shown to be impaired in both 
reflexive and saccadic execution and in the performance of more complex saccadic 
eye movement tasks.40 In addition, problems in convergence are often followed by 
akinesia and rigidity.41 There have also been cases of DLB presenting with a vertical 
and horizontal gaze palsy and these could easily be confused with progressive 
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supranuclear palsy.2,42 Hence, caution is required in the interpretation of deficits in 
vertical gaze palsy when distinguishing the various parkinsonian syndromes.43 
 
Blink reflex  
 
The blink reflex is elicited by a light tap on the glabella, successive taps in normal 
individuals producing less and less response as the reflex habituates. In Parkinson’s 
disease, for example, the blink reflex may not disappear on repeated tapping. This 
affect has, to date, not been studied in DLB but is likely to be present in patients 
exhibiting a significant degree of parkinsonian-type symptoms. The blink reflex to 
electrical stimulation of the supraorbital nerve, however, has been studied in 
parkinsonian patients including those with DLB.44 Blink reflex was significantly 
delayed in the DLB group compared with controls and other parkinsonian groups, 
with a bilateral delay in the latency of the R2 response. There was also a significant 
correlation between the delay in the R2 response and the degree of cognitive 
fluctuation of the patient. Blink reflex has also been studied in DLB patients treated 
with cholinesterase inhibitors.45 Treatment with donepezil, for example, was not 
associated with a change in cognitive or motor performance but after treatment for 
two weeks, the latency of the R2 response was significantly decreased. 
 
Pupil reactivity 
 
Pupillary responses using dilute phenylephrine, a sympathetic agonist and dilute 
pilocarpine, a cholinergic agonist, have been studied in DLB. The mydriatic response 
to 0.5% phenylephrine is greater in DLB than in Alzheimer’s disease while the miotic 
response to 0.0625% pilocarpine is similar in DLB and Alzheimer’s disease, both 
being greater than in control subjects.46 Hence, pupil reactivity tests using 
phenylephrine and pilocarpine may prove useful in the differential diagnosis of 
patients with DLB and Alzheimer’s disease.  
 
Electrophysiology 
 
The electroencephalogram (EEG) to eyes opening and to 12-Hz photic stimulation 
was studied in various groups of patients, including DLB, using global field 
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synchronization (GFS).47 When the eyes were closed, theta-GFS was increased in 
Parkinson’s disease and alpha-1 GFS was decreased in DLB. In addition, using 12-Hz 
intermittent photic stimulation, reactivity of posterior electrodes was also decreased 
in Parkinson’s disease and DLB suggesting disruption of posterior anatomical 
pathways.47 The electroretinogram (ERG) to a flash stimulus has been used to 
demonstrate dysfunction of the photopic and scotopic systems of the retina in DLB 
patients exhibiting visual hallucinations, DLB patients not exhibiting hallucinations, 
Parkinson’s disease, and control patients.48 Retinal dysfunction in the DLB and 
Parkinson’s disease groups was attributed to pathological alterations in the 
photoreceptor cells which were accompanied by an increase of ‘pale inclusions’ in 
the inner plexiform layer. Event related potentials (ERP) have also been studied in 
DLB using a facial discrimination task.49 The mean latency of the visual P3 response 
was greater in DLB than in Alzheimer’s disease and mean latency of the P2 response 
was greater than in controls. The results suggested that visual cognitive functions 
were selectively impaired in DLB and that the impairment may occur at a relatively 
early stage of visual processing. 
 
Complex Visual Functions 
 
Deficits in complex visual function tasks are particularly characteristic of DLB.36,50,51 
Impairments have been identified in object size discrimination, form discrimination, 
overlapping figure identification, drawing common objects such as a clock, and on 
visual counting tasks.51 Patients that develop visual hallucinations are often the worst 
performers on overlapping figure tasks. However, performance on line orientation, 
colour integration, and rotated object comparison tasks were often similar in DLB 
compared with control patients.36 A significant defect in the trail-making task, a test 
of visual attention in which the subject is asked to ‘connect the dots’ on paper or 
computer screen, has been observed in DLB.52  
 
Visual hallucinations 
 
Hallucinations may occur in a significant proportion of cases of both DLB and 
Parkinson’s disease but are much less common in other parkinsonian syndromes such 
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as progressive supranuclear palsy.53 In addition, less frequent auditory hallucinations 
have been observed in DLB.  
 
In the study of Hely et al.,54 hallucinations were present in six out of nine DLB 
patients studied and were the presenting feature in one patient. The visual 
hallucinations were recurrent, well formed and detailed. The presence of visual 
hallucinations may be the only psychotic symptom which reliably discriminates 
between DLB and Alzheimer’s disease. There is considerable overlap between the 
visual hallucinations seen in DLB, however, and those in other types of disorder such 
as the 'misidentification syndromes' and the ‘visual agnosias’. In addition, they are 
similar to those described in association with 'delerium' but differ from those 
produced by hallucinogenic drugs such as LSD. Patients with DLB may see faces 
emerging out of the patterns of chair cushions or curtains or hidden amongst trees or 
flowers and, at the same time, figures may be seen as if they were observed against a 
blank background. Most typically the hallucinations involve people or animals 
invading the patient’s home but may also involve inanimate objects and the 
appearance of writing on walls or ceilings. The hallucinations are often seen in great 
detail and although they may not trouble the patient can evoke considerable fear. 
 
Various factors may be involved in the production of visual hallucinations in DLB 
(Fig 4). Although there may be pathology in some areas of the thalamus,23 visual 
hallucinations in DLB are more likely to be caused by pathology affecting the 
cerebral cortex. Hence, hallucinations are often abolished by eye closure which 
indicates a primary cortical pathology.55 Hypometabolism in area V1 of the visual 
cortex, and relatively preserved metabolism in the temporal and parietal lobes may be 
associated with the development of these symptoms. Well-formed visual 
hallucinations are also evident in patients with extensive development of LB in the 
temporal lobe 25 and are rarely reported in parkinsonian syndromes without LB.53 
Furthermore, cholinergic activity is reduced in the cerebral cortex of patients with 
DLB. More extensive cholinergic abnormalities are believed to be associated with an 
increased risk of visual hallucinations. Hence, hallucinations in DLB could result 
from a change in the balance of neurotransmitter activity between the cholinergic and 
monoaminergic systems as a consequence of LB pathology in brain stem nuclei.56 
Nevertheless, ocular and retinal pathology may also contribute to hallucinations by 
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reducing occipital stimulation.57-59 Pale inclusions were observed in the inner 
plexiform layer of the retina in a patient with DLB. The inclusions were related to 
disorganisation of the cytoskeleton of the cone cells and a modification of the 
distribution of synuclein proteins in the retina.48 As a consequence, downstream 
ventral association areas may increase their activity as a result of cortical 
disinhibition resulting in the hallucinations. 
 
REM sleep behavioural disorder 
 
REM sleep is a normal stage of sleep associated with random movements of the eyes. 
Characteristic of REM sleep behaviour disorder are vivid and frightening dreams 
associated with a simple or complex motor disturbance taking place during REM 
sleep. Patients essentially ‘act out their dreams’ and the condition may have clinical, 
diagnostic, and pathophysiological significance.60 The pathological basis of the 
disorder may be the loss of neurons in the pigmented monoaminergic nuclei such as 
the locus caeruleus and substantia nigra, and which project to the pontine nuclei 
responsible for mediating ‘atonia’ (the inhibition of motor neurons) during REM 
sleep.14 
 
DLB and the optometrist  
 
Detecting the visual problems of the patient 
 
As primary eye-care practitioners, optometrists should be able to identify the visual 
problems of patients with DLB and be expected to work with them and their carers to 
manage their visual welfare. The optometrist has a role in helping a patient with DLB 
if it is believed that signs and symptoms of the disease are present. As in Parkinson’s 
disease, visual symptoms of DLB are highly variable, patients exhibiting various 
combinations of such symptoms.1 In addition, the literature regarding the visual 
changes in DLB is limited compared with that in Parkinson’s disease1 and 
progressive supranuclear palsy.2 Existing data are also controversial, different studies 
often giving conflicting results. A number of tests and procedures may be useful in 
identifying the visual problems of patients with a parkinsonian syndrome including 
DLB. It is particularly important to carry out the full examination including ocular 
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health assessment. Subsequently, several additional tests may be helpful and these 
have been described in detail in a previous review of progressive supranuclear palsy2 
and are equally applicable to DLB.  
 
Differential diagnosis  
 
The clinical symptoms of DLB overlap with those of both Alzheimer’s disease and 
Parkinson’s disease which can make differential diagnosis difficult especially in the 
early stages of the disease. In addition, the exact presentation of DLB will vary and 
some patients will not exhibit any overt visual symptoms. It is not the role of the 
optometrist to attempt a diagnosis of DLB or to be able to separate the condition from 
other parkinsonian syndromes and from Alzheimer’s disease. Nevertheless, 
optometrists may provide useful additional information regarding the visual problems 
of the patient that may be helpful subsequently in a differential diagnosis. One of the 
main difficulties is distinguishing DLB from Parkinson’s disease, especially early in 
the disease. A correct diagnosis is important because patients with visual 
hallucinations may be treated with antipsychotic drugs, a hazardous treatment in 
DLB.34  
 
Many of the parkinsonian syndromes have overlapping clinical features and it can be 
difficult to diagnose an individual case. In patients with unclassifiable or with 
indeterminate parkinsonian symptoms, the presence of visual hallucinations should be 
regarded as a ‘red flag’ symptom indicating underlying LB pathology61 and therefore, 
supporting a diagnosis of Parkinson’s disease or DLB rather than progressive 
supranuclear palsy or MSA.  Generally, DLB patients exhibit fewer tremors, more 
asymmetry of motor symptoms, more falls, and respond less to dopamine treatment 
than Parkinson’s disease.62 DLB and Parkinson’s disease show similar impairments 
on a variety of saccadic eye movement tasks. A newly developed portable 
saccadometer has been used to compare saccadic latency distribution in several 
parkinsonian syndromes63 and a combination of saccadic parameters may give greater 
discrimination between Parkinson’s disease and DLB than a single parameter such as 
median latency. There are also similarities in general cognitive performance in 
Parkinson’s disease and DLB but there are some subtle differences. For example, 
deficits in orientation, ‘trail-making’, and reading the names of colours (‘Stroop test’) 
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would support a diagnosis of DLB rather than Parkinson’s disease.52 Visual 
perception tasks (visual discrimination, space-motion and object-form recognition), 
however, are usually equally impaired in DLB and Parkinson’s disease, especially in 
patients with visual hallucinations.64 In addition, cognitive/psychiatric symptoms are 
generally less frequent in Parkinson’s disease than in DLB.65 
 
Many of the clinical signs and symptoms of DLB can also be seen in patients with 
Alzheimer’s disease66-69 but there may be a specific pattern of cognitive/psychiatric 
symptoms of dementia which can be used to differentiate DLB from Alzheimer’s 
disease.70 The presenting symptoms of DLB vary considerable but a clinical 
diagnosis of the disorder may be suspected when certain features are present. For 
example, although visual hallucinations may be present in Alzheimer’s disease69 they 
are much more pronounced and vivid in DLB.10 In addition, functional brain imaging 
reveals hypometabolism in the visual cortex in DLB, a feature not so frequently 
present in Alzheimer’s disease.71 Other prominent features of DLB include 
fluctuating cognitive impairment, episodes of confusion and parkinsonism together 
with many of the visual signs and symptoms of Parkinson’s disease.1 Impairment of 
short-term memory, myoclonus (involuntary limb jerking), disturbances of gait and 
posture, and varying degrees of depression may also be present in DLB. In addition, 
pupil reactivity tests using phenylephrine and pilocarpine and electrophysiology may 
prove useful in the differential diagnosis of patients with DLB and Alzheimer’s 
disease. 
 
Practical ways the optometrist can help 
 
As in Alzheimer’s disease69 and other parkinsonian syndromes,1,2 patients with DLB 
are likely to have visual problems that may not have been detected due to the 
developing disease. Patients with neurodegenerative disease are also less likely to be 
able to describe their visual problems effectively and are more likely to experience 
and tolerate visual deficits.72 Optometrists can refer patients to other health-care 
professionals for treatment and evaluation. For example, patients with visual 
hallucinations can be referred to clinical psychologists for counseling. 
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Care giving is particularly important in DLB as the disease gradually reduces the 
ability of an individual to look after themselves. One factor in improving the quality 
of life of DLB patients and as a consequence, reducing the burden on those that care 
for them, is for the patient to be able to see as clearly as possible. This is particularly 
important in DLB because visual hallucinations are exacerbated by other visual 
impairments and may be temporally relieved by environmental stimulation. Hence, it 
is important that the visual problems present should be investigated and detected and 
those due to ocular factors corrected as far as possible. In addition, various 
procedures may help the patient cope with the visual symptoms of DLB. DLB 
patients fall more readily resulting in a sedentary life style and if vertical gaze palsy 
is present, the patient may develop reading problems and eating difficulties. New 
devices are being tested in which refraction-positive moveable prism glasses are 
placed in front of the eyes to help patients with these problems.73 In addition, it is 
important to bring to the attention of carers those visual problems of the patient that 
cannot be easily corrected such as oculomotor apraxia or possible visual field defects. 
As a consequence, carers may be able to make some provision for these problems, 
e.g., by simplifying the visual environment of the patient or by careful positioning of 
objects. 
 
Conclusion 
 
DLB is a common neurodegenerative syndrome of elderly people characterized by 
symptoms that can resemble those seen in other parkinsonian syndromes such as 
Parkinson’s disease and progressive supranuclear palsy. The signs and symptoms of 
DLB can also resemble those of Alzheimer’s disease. Where visual signs and 
symptoms are present, they may help in a differential diagnosis of DLB and 
especially in separating the disorder from Parkinson’s disease. A diagnosis of 
probable DLB is important to prevent the prescribing of specific antipsychotic 
medications. Diagnosis may also benefit the patient because there may be visual 
problems present that need to be recognized and which can be subsequently managed 
by the eye-care practitioner. 
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Table 1. Criteria for the diagnosis of dementia with Lewy bodies (DLB) (Mckeith et 
al., 1996). 
_____________________________________________________________________ 
 
1. Progressive cognitive decline which interferes with social or occupational 
function. Memory deficit apparent at some stage. Deficits on tests of attention 
and visuo-spatial tasks prominent. 
 
 2. Two of the following features: 
  a) Fluctuating cognition 
  b) Recurrent visual hallucinations 
  c) Motor features of Parkinson's disease 
 
 3. Additional features which support diagnosis: 
  a) Repeated falls 
  b) Syncope 
  c) Transient loss of consciousness 
  d) Neuroleptic sensitivity 
  e) Systematised delusions 
  f) Non-visual hallucinations 
 
4. A diagnosis of DLB is less likely if there is evidence of vascular disease of 
the brain. 
_____________________________________________________________________ 
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Table 2. Visual signs and symptoms of dementia with Lewy bodies (DLB). 
(Alzheimer’s disease = Alzheimer’s disease, Parkinson’s disease = Parkinson's 
disease) 
 
_____________________________________________________________________ 
Ocular aspect    Change in DLB  References 
 
Visual fields  Homonymous hemianopia may Bashir et al., 1998 
occur early in disease process  
  
Eye movements Impaired reflexive and saccadic Mosimannn et al., 2005 
   execution     
Convergence  problems followed Debruin et al., 1992 
by akinesia and rigidity   
Vertical and horizontal gaze palsy Fearnley et al., 1991   
 
   
Blink reflex  R2 response significantly delayed Bonnani et al., 2007  
to stimulation of supraorbital 
nerve 
R2 decreased after donepezil  Anzelloti et al., 2008 
Treatment 
 
Pupillary reactivity Mydriatic response to pilocarpine Hanyu et al., 2007 
   and phenylephrine 
    
 
Electrophysiology EEG: alpha-1 GFS decreased  Pugnetti et al., 2010 
   ERG: dysfunction in patients  Devos et al., 2005 
   with hallucinations     
   ERP: P3 latency increased  Kurita et al., 2010  
  
 28
Complex visual Abnormalities in object size  Mori et al., 2000 
tasks   discrimination, form 
discrimination, overlapping 
figure identification, visual 
counting tasks, drawing simple 
objects, copying figures 
 
Visual hallucinations More frequent in DLB than Alzheimer’s disease Galasko et 
al., 1996 
and may be presenting feature in Hely et al., 1996 
a proportion of patients   
_____________________________________________________________________ 
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Legends to Figures 
 
Fig 1. The areas of the brain affected by the pathology of dementia with Lewy bodies 
(DLB) (shown in bold in large font) (SFC = superior frontal cortex, OC = Occipital 
cortex, STG = Superior temporal gyrus, PHG = Parahippocampal gyrus, HC = 
Hippocampus, CG = Cingulate gyrus, I/C = Insula/claustrum, A = Amygdala, nB = 
Nucleus basalis of Meynert, Put = Putamen, CN = caudate nucleus, P = Pulvinar of 
thalamus, SN = Substantia nigra, R = Raphe nuclei, LC = Locus careuleus, Other 
areas identified (in normal text and small font) (OG = orbital gyrus, GR = Gyrus 
rectus, PC = Parietal cortex, DG = Dentate gyrus, Th = Thalamus, LGN = lateral 
geniculate nucleus, Hy = Hypothalamus, VT = Ventral tegmentum, Ce = Cerebellum, 
MB = Mamillary bodies, GP = Globus pallidus) superimposed on a two-dimensional 
model of the brain based on that of WJH Nauta and M Feirtag (1986) Fundamental 
Neuroanatomy. WH Freeman & Co. Hence the cerebral cortex is represented at the 
right of the diagram with the striatum (ST) and thalamus (Th) below. Midbrain and 
brain stem nuclei are at the left of the diagram. 
 
Fig 2. Section through the cerebral cortex of a patient with dementia with Lewy 
bodies (DLB) showing the presence of Lewy bodies (LB) (arrow) within the neurons. 
These structures probably represent abnormalities of the neuronal cytoskeleton 
resulting from degeneration (Section immunolabelled with antibodies against -
synuclein). 
 
Fig 3. Density of Lewy bodies (LB) in various brain areas, averaged over 12 cases of 
DLB. The greatest densities of LB are seen in the temporal lobe and in limbic 
regions, especially the parahippocampal gyrus (PHG), amygdala (AM), superior 
temporal gyrus (STG) and middle temporal gyrus (MTG). Significant numbers of LB 
are also seen in the substantia nigra (SN) as in Parkinson’s disease, the cingulate 
gyrus (CG), and the insular cortex (IC) while fewer LB have been recorded in the 
frontal (SFG), sector CA1 of the hippocampus, parietal cortex (PC), and occipital 
regions (OC). 
 
Fig 4. Factors involved in the production of visual hallucinations in dementia with 
Lewy bodies (DLB). Abbreviations: LB = Lewy bodies LB, TL = Temporal lobe, 
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CHOL = Cholinergic neurotransmitter system, NA = Noradrenergic neurotransmitter 
system. 
 
 
 
 
 
 
 
